ArticleInvestigational new drugs2014

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine.

Lawrence M Gelbert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.